Bisphosphonates therapy for osteoarthritis: a meta-analysis of randomized controlled trials by unknown




for osteoarthritis: a meta-analysis of randomized 
controlled trials
R. L. Xing, L. R. Zhao and P. M. Wang*
Abstract 
High-turnover type bone metabolism derangement has been considered to be one of the major causes of osteoar-
thritis (OA). Bisphosphonates can attach to hydroxyapatite binding sites on bony surfaces, particularly those which are 
undergoing active bone resorption. To evaluate the effectiveness of bisphosphonates in OA treatment, literature data-
bases were searched from inception to February 28, 2016 for clinical studies of bisphosphonates for OA treatment. 
All randomized controlled trials in which bisphosphonates therapy was compared with a placebo or a conventional 
medication, were selected. 15/1145 studies were eligible for analysis, which included 3566 participants. Bisphos-
phonates therapy improved pain, stiffness and function significantly in OA assessed by the Western Ontario and 
McMaster Universities Arthritis Index scale (MD = 4.59; 95 % CI 2.83–6.34; P < 0.00001; MD = 1.43; 95 % CI 0.83–2.23; 
P = 0.0005; MD = 2.01; 95 % CI 1.27–2.75; P < 0.00001). Bisphosphonates also reduced osteophyte score significantly 
(MD = −0.51; 95 % CI −0.84 to −0.19; P = 0.002). However, no significant differences were found in subjective 
improvement, osteoarthritis progression, the number of required acetaminophen treatment or joint replacement. In 
conclusion, bisphosphonates therapy is effective in relieving pain,stiffness and accelerating functional recovery in OA. 
Limitations of the studies we analysed included the differences in duration of bisphosphonates use, the doses and 
types of bisphosphonates and the lack of long-term data on OA joint structure modification after bisphosphonates 
therapy. More targeted studies are required to evaluate on the effectiveness of bisphosphonates for OA treatment.
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Background
Osteoarthritis (OA) is the most common form of arthri-
tis. It is a major cause of disability among the ageing 
population. The affected joint is undergoing a complex 
combination of degradative and reparative processes 
(Collins et al. 2016a; Palazzo et al. 2016), the mechanism 
of which is still unclear. There are currently no treat-
ments that delay or halt OA progression.
The main clinical manifestations include pain, swell-
ing and disability caused by topical cartilage loss, sub-
chondral bony changes, osteophyte formation and 
synovitis (Liu et al. 2016). OA has long been believed as 
a cartilage disease, but more recent evidence suggests 
that periarticular bone abnormality is also involved in 
the disease initiation and progression (Kalunian 2016). 
Decreased bone mineral content and trabecular numbers 
in subchondral bone structure in the early OA have been 
observed by magnetic resonance imaging (Madry et  al. 
2016). High-turnover type bone metabolism derange-
ment has been considered as a main cause of OA (Collins 
et al. 2016b).
Previous experimental studies on bone anti-resorptive 
agents for OA have shown promising results (Fenty et al. 
2012). The Duncan-Hartley guinea pig model is a widely 
used spontaneous model of OA progression, which is 
characterized by subchondral bony changes (Sun et  al. 
2015). In rat anterior cruciate ligament transection 
(ACLT) models of KOA, alendronate could protect car-
tilage from degeneration and inhibit subchondral bone 
remodeling (Strassle et al. 2010).
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Bisphosphonates can inhibit bone resorption and there-
fore they are the mainstream medications for osteoporo-
sis. But for OA treatment, there is no official statement 
or guideline for bisphosphonates therapy. Recently, more 
and more evidence have shown bisphosphonates are effec-
tive in OA treatment. Bisphosphonates can suppress local 
bone turnover or inhibit the level of local pro-inflamma-
tory cytokines. Further studies confirmed that defective 
subchondral bone metabolism in OA could alter chon-
drocytes during subchondral bone remodeling. Increased 
subchondral bone turnover may contribute to pain in OA, 
which may be relieved by targeting osteoclasts. Although 
bisphosphonates therapy seems to have positive effects on 
OA, these effects have not been extensively studied. To our 
knowledge, only one systematic review and meta-analy-
sis was conducted with a limited number of poor-quality 
RCTs, which demonstrated limited evidence of bisphos-
phonates for pain relief in OA (Davis et al. 2013). Moreo-
ver, osteoarthritis progression, required acetaminophen 
treatment and joint replacement were not analyzed.
Therefore, this review aims to summarize the results of 
these clinical trials and evaluate the clinical effects, which 
may be useful to clinical practice. This meta-analysis was 
conducted in accordance with Cochrane guidelines (Hig-
gins and Green 2011).
Methods
Search strategies
All searches were conducted from database MEDLINE, 
PubMed, EMBASE, and the Cochrane Central Register of 
Controlled Trials (CENTRAL) from inception to Febru-
ary 28, 2016. The MeSH terms we used were (Osteoarthri-
tis) AND (OA) AND (Bisphosphonates). To ensure a more 
complete meta-analysis, we used a maximally sensitive 
search for RCTs according to the Cochrane Highly Sensi-
tive Search Strategy. Systematic review and meta-analysis 
were manually searched as references for included studies.
Inclusion criteria
The inclusion criteria were (1) RCTs comparing bis-
phosphonates with any control methods, include a pla-
cebo or a conventional medication. And published as 
peer-reviewed indexed papers; (2) patients with estab-
lished OA administering medication or other control 
interventions; (3) studies detailing the type and dosage 
of medications and treatment course; (4) primary out-
comes included visual analogue scale (VAS) pain score, 
WOMAC pain, stiffness, function score and osteophyte 
score, while secondary outcomes included subjective 
improvement, osteoarthritis progression and the number 
of required acetaminophen treatment or joint replace-
ment. Studies reported at least two of the primary out-
comes. (5) Literature in English.
Exclusion criteria
The exclusion criteria were (1) non-randomized con-
trolled trials; (2) studies without available data; (3) dupli-
cate publications among authors or centers.
Data extraction and quality assessment
Data from all eligible papers were extracted and inde-
pendently verified. Data extracted included study charac-
teristics, patient characteristics, primary and secondary 
outcomes.
Study characteristics included study design, name of 
first author, sample size and follow-up period. Patient 
characteristics included the number of patients, gender, 
affected joint, type of intervention and dosage. If a study 
reported the outcomes of multiple doses of bisphospho-
nates, only data of the maximum dose were extracted 
for analysis. If a study reported the outcomes of multiple 
time points after treatment, only data of the final follow-
up time point was extracted for analysis.
The methodological quality of each included study 
was evaluated in accordance with the Cochrane Col-
laboration’s risk of bias tool (Higgins and Green 2011), 
which used the following items as random sequence 
generation, allocation concealment, blinding of outcome 
assessors,patients and other participants, incomplete 
outcome data, selective reporting of outcomes and other 
biases. The bias risk of each item was graded as low, high 
or unclear.
Statistical analysis
All statistical analyses were conducted with RevMan ver-
sion 5.3 software (provided by Cochrane Collaboration). 
Heterogeneity was evaluated with Q tests and I2, and 
P  <  0.10 was determined as significant. If there was no 
or low heterogeneity then the fixed-effects model was 
used. Otherwise, the random-effects model was used. 
The risk ratio (RR) was calculated for dichotomous data, 
and weighted mean differences (WMD) or standard 
mean differences (SMD) were used for continuous vari-
ables. Both differences were presented with 95 % CI. For 
continuous variables, if data were presented with medi-
ans and ranges, then the means and SDs were calculated 
according to Hozo et al. (2005). If the study presented the 
median and interquartile range, the median was treated 
as the mean, and the interquartile ranges were calculated 
using 1.35 SDs, as described in the Cochrane handbook.
Results
Search results
The results of the literature search strategy identified a 
total of 1145 papers. 294 full texts were reviewed and a 
total of 15 papers were deemed eligible and included in 
this systematic review (covering a total of 3566 patients, 
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including 1517 in bisphosphonates group and 2049 in 
control groups) (Fig. 1). (Neogi et al. 2008; Rossini et al. 
2015; Laslett et  al. 2014; Nishii et  al. 2013; Arti and 
Azemi 2012; Laslett et al. 2012; Saviola et al. 2012; Fujita 
et al. 2011; Rossini et al. 2009; Fujita et al. 2009; Bingham 
et al. 2006; Spector et al. 2005; Carbone et al. 2004; Fujita 
et al. 2001).
Characteristics of included studies
Of the 15 eligible studies, 1517 patients received bispho-
sphonates therapy, and 2049 patients received control 
interventions. The baseline characteristics were similar 
among these trials (Table 1).
Methodological quality of studies
The quality assessment of the trials was performed 
using the Cochrane Collaboration’s Risk of Bias tool. 
The results of quality assessment illustrated there were 
some methodological limitations in these studies, qual-
ity of which was moderate (Fig.  2). Random sequence 
generation was described clearly in 6 studies (40  %) 
and unclearly in 8 studies (53 %). 3 studies (20 %) had a 
high risk of bias relating to allocation concealment, and 
12 studies (80 %) had an unclear risk of bias relating to 
allocation concealment. Only 7 studies (46.7  %) blinded 
outcome assessors and the blindness in 5 studies (33.3 %) 
were unclear. All RCTs had a low risk of bias relating to 
incomplete outcome data and selective reporting. Biases 
relating to other aspects were unclear.
Meta‑analysis
Primary outcome parameters
VAS pain score: the results of 6 studies (627 patients) 
with combined data indicated that bisphosphonates 
therapy improved pain nosignificantly assessed by VAS 
pain scores (MD = 0.80; 95 % CI −1.13 to 2.73; P = 0.42) 
compared with respective control group (Fig. 3).
WOMAC pain score: the results of 5 studies (1879 
patients) with combined data indicated that bisphos-
phonates therapy improved pain significantly assessed 
by WOMAC pain score (MD = 4.59; 95 % CI 2.83–6.34; 
P  <  0.00001) compared with respective control group 
(Fig. 4).
WOMAC stiffness score: the results of 3 studies (1757 
patients) with combined data indicated that bisphospho-
nates therapy improved stiffness in affected joints signifi-
cantly assessed by WOMAC stiffness score (MD = 1.43; 
95 % CI 0.83–2.23; P = 0.0005) compared with respective 
control group (Fig. 5).
WOMAC function score: the results of 3 studies (1757 
patients) with combined data indicated that bispho-
sphonates therapy improved the function of affected 
joints significantly assessed by WOMAC function scores 
(MD = 2.01; 95 % CI 1.27–2.75; P < 0.00001) compared 
with respective control group (Fig. 6).
Osteophyte score: the results of 4 studies (1125 
patients) with combined data indicated that bispho-
sphonates therapy relieved osteophyte formation in 
affected joints significantly assessed by osteophyte score 
(MD = −0.51; 95 % CI −0.84 to −0.19; P = 0.002) com-
pared with respective control intervention (Fig. 7).
Secondary outcome
There were no significant differences in osteoarthritis 
progression (3 studies including 2578 patients), required 
acetaminophen treatment (3 studies including 940 
patients) and joint replacement (3 studies including 424 
patients) between the application of bisphosphonates 
therapy and respective control intervention (Figs. 8, 9, 10, 
11).
Discussion
This meta-analysis demonstrated bisphosphonates ther-
apy in OA had better effect on joint pain, stiffness and 
function, although it had no better effect on osteoarthri-
tis progression, required acetaminophen treatment and 
joint replacement comparing to other medications. How-
ever, there was some heterogeneity across the included 
studies as for pain, stiffness and function scores, which 
may result from variation in the types or doses of bispho-
sphonates in different studies. When a sensitivity analysis 
was performed, the heterogeneity disappeared.
Current pharmacologic therapies for OA aim majorly 
to symptom control with analgesics, non-steroidal anti-
inflammatory drugs (NSAIDs) and COX-2 inhibitors 
(Smith et  al. 2016). NSAIDs, a most commonly used 
medication in symptomatic OA management, are found 
to be associated with gastrointestinal adverse reaction Fig. 1 Flow chart of study selection
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dose-related risks of renal toxicity and cardiovascular 
diseases (Brown 2013). Glucosamine has been suggested 
as a potential structure-modifying OA drug, but the data 
concerned are inconsistent (Krader 2014). Increased evi-
dence suggests that high turnover metabolism derange-
ment plays an important role in the initiation and 
progression of OA, which has resulted in an increased 
level of interest in drugs that affecting bone metabolism 
may slow the progression of OA (McGrory et al. 2016).
Based on 15 RCTs, this meta-analysis indicated that 
bisphosphonates therapy have better effect in reliev-
ing pain and accelerating functional recovery for OA. In 
our study, there were no significant differences on the 
number of required acetaminophen treatment and joint 
replacement between bisphosphonates therapy and other 
conventional medications. But the causes that patients 
received NSAID were various, and few researchers pro-
vided the details of clinical stage and pathological grade 
of their patients. Therefore, further studies are needed to 
provide more solid evidence.
Quality of the evidence
The overall methodological quality was moderate, and 
most studies had at least one aspect of unclear or high 
risk of bias. Not all outcome assessors were blinded, 
which may produce performance or measurement biases. 
Selection bias may exist since only 3 studies used allo-
cation concealment. As bisphosphonates are only be 
evaluated as “off label” therapy for OA, there was no cor-
responding standardized treatment guideline. Although 
we had performed sensitivity analysis, the effect of bis-
phosphonates may be underestimated.
Table 1 Characteristics of 15 RCTs included
OST spinal osteophytes, DSN disc-space narrowing, WOMAC Western Ontario McMaster Universities (WOMAC) Osteoarthritis Index, VAS Visual Analogue Scale, JSW: 
joint space width, HS hand strength, NOSPJ number of swollen and painful joints, PGA Patient Global Assessment, LI Lequesne Index, KOOS Knee Injury and OA 
Outcome Score















200 65.8 ± 6.1
66.1 ± 6.4
Spine Radiographs 24 OST, DSN Alendronate VS 
placebo




80 66 ± 6 Knee Radiographs 3 WOMAC, VAS Clodronate VS 
placebo




323 59.8 ± 8
66.7 ± 7.4









42 54.7 ± 8.5
58.3 ± 8.8








130 60.9 ± 9.9 Knee Radiographs 3 WOMAC Alendronate VS 
glucosamine




53 64.2 ± 8.2
60.4 ± 7.3
Knee Radiographs 12 VAS,KOOS; Zoledronic VS 
placebo





29 60.0 ± 7.1
63.5 ± 7.4
Hand Radiographs 24 VAS, HS, NOSPJ Clodronate VS 
HCQ




38 69 ± 8
68 ± 9
Spine, knee Radiographs 6 VAS, SF-36 Risedronate VS 
Elcatonin




150 64.7 ± 7.4
65.2 ± 6.9
Knee Radiographs 18 VAS, LI Clodronate VS 
Hyaluronic acid





100 68 ± 9.0
66 ± 8.0






627 60.3 ± 2.6
63.1 ± 2.3
Knee Radiographs 24 JSW Risedronate VS 
placebo




2483 60.7 ± 0.5
60.2 ± 0.5
Knee Radiographs 24 WOMAC, JSW, Risedronate VS 
placebo




285 63.8 ± 0.9
63.2 ± 0.8
Knee Radiographs 12 WOMAC; PGA Risedronate VS 
placebo




818 74.8 ± 2.9
74.8 ± 2.9








80 65 ± 7 Spine, knee Radiographs 12 VAS Etidronate VAS 
placebo
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Conclusions
This meta-analysis showed that bisphosphonates ther-
apy is effective for patients with OA in relieving pain 
and accelerating functional recovery. However, the 
conclusions are limited due to small sample sizes and 
methodological study quality, the different doses and 
treatment courses among studies. Further studies are 
needed to provide more solid evidence.
a
b
Fig. 2 Methodological quality assessment according to the Cochrane Collaboration’s Risk of Bias tool study
Fig. 3 Change of Visual Analogue Scale (VAS) Pain Score
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Fig. 4 Change of WOMAC-Pain. The first Bingham et al. (2006) refers to the outcomes from 44 European centers (11 countries), the second Bingham 
refers to the outcomes from 42 centers in North America (US and Canada); The first Rossini et al. (2015) refers to the outcomes of 8 weeks follow-up, 
the second Rossini et al. (2015) refers to the outcomes of 16 weeks follow-up
Fig. 5 Change of WOMAC-Stiffness. The first Bingham et al. (2006) refers to the outcomes from 44 European centers (11 countries), the second 
Bingham refers to the outcomes from 42 centers in North America (US and Canada)
Fig. 6 Change of WOMAC-Function. The first Bingham et al. (2006) refers to the outcomes from 44 European centers (11 countries), the second 
Bingham refers to the outcomes from 42 centers in North America (US and Canada)
Fig. 7 Change of Osteophyte Score. The first Neogi et al. (2008) refers to the outcomes of adjusted change in summary osteophyte score, the 
second Neogi et al. (2008) refers to the outcomes of adjusted change in summary disc-space narrowing score
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